Physician profile
Stephen Heller
NPI 1093826588
$8,321.51
in general payments reported to CMS, 2019-2025
21 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.17 · 2021: $834 · 2022: $1,288 · 2023: $1,288 · 2024: $3,522 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,096 · Food and Beverage: $2,007 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,096.25 |
| Food and Beverage | $2,007.30 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation | $3,347.50 | 2021-2023 | Evis Exera III Video System Center |
| Olympus Medical Systems Corporation | $2,808.75 | 2024 | |
| Abbvie INC. | $566.42 | 2024-2025 | |
| Janssen Biotech, INC. | $256.66 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $255.35 | 2024-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $158.02 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.41 | 2024-2025 | Xifaxan, Trulance, Plenvu |
| Celltrion USA INC. | $116.56 | 2024-2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $113.98 | 2024-2025 | Dupixent |
| Boston Scientific Corporation | $103.19 | 2019-2024 | |
| Pfizer INC. | $102.32 | 2024-2025 | |
| Ardelyx, INC. | $101.58 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $76.45 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $41.56 | 2024 | |
| Phathom Pharmaceuticals, INC. | $32.75 | 2024-2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $26.05 | 2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $22.64 | 2024 | Rebyota |
| Daiichi Sankyo INC. | $18.30 | 2024 | Injectafer |
| Aimmune Therapeutics, INC. | $18.03 | 2024 | |
| Intercept Pharmaceuticals, INC. | $14.49 | 2024 | |
| Conmed Corporation | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.